Abstract
The decision to anti-coagulate patients with heart failure (HF) is a difficult one, with limited data available to support clinical judgment. Thromboembolic complications, both arterial (stroke) and venous (deep vein thrombosis and pulmonary embolism), remain a significant cause of mortality and morbidity in this population. The pathophysiology of thrombogenesis in HF may be contextualized in the classic triad of stasis, endothelial dysfunction and hypercoagulability. Dilated cardiac chambers, reduced systolic function, and left ventricular aneurysm or thrombus have been suggested as potential contributing factors. HF is associated with activation of inflammatory and neuroendocrine pathways, leading to endothelial dysfunction and a prothrombotic state with dysregulated platelets and activation of the coagulation cascade. The epidemiology of thromboembolic events in HF is poorly defined. Most studies are retrospective and include patients with concurrent atrial fibrillation. The current body of health outcomes research is reviewed to identify the specific etiological factors, prevalence, and impact of thromboembolic events in this patient population. Conflicting analyses exist regarding the risks and benefits of prophylaxis in HF. The data surrounding several classes of therapeutic agents are synthesized. Recent clinical trials on anticoagulation and HF are reviewed, including WATCH, WASH, and WARCEF. The absence of compelling clinical trial data leaves many unanswered questions regarding systemic anticoagulation in patients with HF.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Anticoagulation in Patients with Heart Failure
Volume: 7 Issue: 3
Author(s): R. Sacha Bhatia, Maral Ouzounian, Jack V. Tu, Peter P. Liu and Douglas S. Lee
Affiliation:
Abstract: The decision to anti-coagulate patients with heart failure (HF) is a difficult one, with limited data available to support clinical judgment. Thromboembolic complications, both arterial (stroke) and venous (deep vein thrombosis and pulmonary embolism), remain a significant cause of mortality and morbidity in this population. The pathophysiology of thrombogenesis in HF may be contextualized in the classic triad of stasis, endothelial dysfunction and hypercoagulability. Dilated cardiac chambers, reduced systolic function, and left ventricular aneurysm or thrombus have been suggested as potential contributing factors. HF is associated with activation of inflammatory and neuroendocrine pathways, leading to endothelial dysfunction and a prothrombotic state with dysregulated platelets and activation of the coagulation cascade. The epidemiology of thromboembolic events in HF is poorly defined. Most studies are retrospective and include patients with concurrent atrial fibrillation. The current body of health outcomes research is reviewed to identify the specific etiological factors, prevalence, and impact of thromboembolic events in this patient population. Conflicting analyses exist regarding the risks and benefits of prophylaxis in HF. The data surrounding several classes of therapeutic agents are synthesized. Recent clinical trials on anticoagulation and HF are reviewed, including WATCH, WASH, and WARCEF. The absence of compelling clinical trial data leaves many unanswered questions regarding systemic anticoagulation in patients with HF.
Export Options
About this article
Cite this article as:
Bhatia Sacha R., Ouzounian Maral, Tu V. Jack, Liu P. Peter and Lee S. Douglas, Anticoagulation in Patients with Heart Failure, Cardiovascular & Hematological Agents in Medicinal Chemistry 2009; 7 (3) . https://dx.doi.org/10.2174/187152509789105462
DOI https://dx.doi.org/10.2174/187152509789105462 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Current Stem Cell Research & Therapy Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Near Infrared Optical Technologies to Illuminate the Status of the Neonatal Brain
Current Pediatric Reviews Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology Functional Effects of Levosimendan in Rat Basilar Arteries In Vitro
Current Neurovascular Research Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews Why Does Obesity Increase the Risk for Cardiovascular Disease?
Current Pharmaceutical Design Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Hypertension in Pregnancy: A Review of Current Guidelines
Current Women`s Health Reviews Role of Contrast-Enhanced Ultrasound in the Follow-up of Endo-Vascular Aortic Aneurysm Repair: an Effective and Safe Surveillance Method
Current Pharmaceutical Design Oxidative Stress in the ICU
Current Nutrition & Food Science Targeting Strategies to Modulate the NF-κB and JNK Signal Transduction Network
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Cancer Stem Cells with Natural Products
Current Drug Targets The Injured Cochlea as a Target for Inflammatory Processes, Initiation of Cell Death Pathways and Application of Related Otoprotective Strategies
Recent Patents on CNS Drug Discovery (Discontinued) Multi-scale LBP and SVM Classification to Identify Diabetic Retinopathy in Lesions
Current Medical Imaging The Role of Phase Image in the Detection of Myocardial Dyskinesia by Magnetic Resonance Imaging (MRI)
Current Medical Imaging Anesthetic Cardioprotection: The Role of Adenosine
Current Pharmaceutical Design Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology